IperionX (NASDAQ:IPX) Trading 5.1% Higher - Should You Buy?

Key Points

• Shares of IperionX were trading up about 5.1% to $23.09 intraday (high $23.39) on thin volume of 62,426 shares, roughly 73% below the average session volume.
• Analysts have a consensus rating of Moderate Buy with an average price target of $55.33, reflecting mixed views (four Buy ratings and one Sell) and price targets ranging roughly $40–$74.
• The company shows strong liquidity (current ratio 4.03, quick ratio 4.00, debt/equity 0.03) but remains unprofitable (last quarter EPS -$0.50; FY forecast -$0.08) and currently trades well below its 50- and 200-day moving averages (around $42).

Shares of IperionX Limited Sponsored ADR (NASDAQ:IPX - Get Free Report) traded up 5.1% during mid-day trading on Friday . The company traded as high as $23.39 and last traded at $23.09. 62,426 shares changed hands during trading, a decline of 73% from the average session volume of 231,885 shares. The stock had previously closed at $21.98.

Analyst Ratings Changes

A number of research firms have weighed in on IPX. William Blair initiated coverage on IperionX in a research note on Tuesday, January 13th. They issued an "outperform" rating on the stock. B. Riley Financial reduced their price target on shares of IperionX from $58.00 to $52.00 and set a "buy" rating on the stock in a research note on Friday, March 13th. BTIG Research assumed coverage on shares of IperionX in a report on Friday. They set a "buy" rating and a $40.00 price objective for the company. Weiss Ratings restated a "sell (e+)" rating on shares of IperionX in a research note on Thursday, January 22nd. Finally, Roth Mkm reaffirmed a "buy" rating and set a $74.00 price target on shares of IperionX in a research note on Tuesday, January 20th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $55.33.

IperionX Trading Up 8.1%

The company has a current ratio of 4.03, a quick ratio of 4.00 and a debt-to-equity ratio of 0.03. The company's fifty day simple moving average is $43.19 and its 200-day simple moving average is $42.36.

IperionX (NASDAQ:IPX - Get Free Report) last announced its quarterly earnings results on Saturday, January 31st. The company reported ($0.50) earnings per share for the quarter. As a group, equities research analysts forecast that IperionX Limited Sponsored ADR will post -0.08 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Cape Investment Advisory Inc. bought a new position in shares of IperionX in the 2nd quarter worth $34,000. Jones Financial Companies Lllp bought a new stake in IperionX during the third quarter valued at about $36,000. JPMorgan Chase & Co. purchased a new position in IperionX in the second quarter valued at about $66,000. State of Tennessee Department of Treasury bought a new position in IperionX in the fourth quarter worth about $119,000. Finally, DV Equities LLC purchased a new stake in shares of IperionX during the fourth quarter valued at about $178,000. 2.76% of the stock is currently owned by hedge funds and other institutional investors.

IperionX Company Profile

IperionX NASDAQ: IPX is a mineral technology company focused on the production and commercialization of high‐purity titanium and zirconium products. The company’s core activities include the development of advanced mineral sands projects and the deployment of proprietary processing technologies aimed at supplying feedstocks to aerospace, defense, additive manufacturing and battery markets.

At the heart of IperionX’s operations is the Stony Creek Project in Virginia, where the company holds significant mineral sands rights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.